华大基因：三季度单季营收重回增长 降本增效助推盈利改善

Core Viewpoint - BGI Genomics reported a strong financial performance in Q3 2025, with significant growth in net profit despite industry challenges [1][2] Financial Performance - Q3 revenue reached 1.042 billion yuan, a year-on-year increase of 9.19%, while net profit attributable to shareholders grew by 80.92% [1] - For the first three quarters, total revenue was 2.674 billion yuan, with net profit increasing by 82.78% and non-recurring net profit up by 52.04% [1] Business Segment Performance - The reproductive health segment saw revenue of 643 million yuan, a decline attributed to the non-invasive prenatal testing business [1] - The oncology and chronic disease prevention segment generated 358 million yuan, slightly down due to reduced client testing demand [2] - The infection control segment achieved 75 million yuan in revenue, a 41.7% increase, driven by advancements in pathogen sequencing and automation [2] Strategic Adjustments - The company is actively adjusting its business strategies to enhance high-margin product growth and improve operational efficiency [2] - Future outlook suggests a commitment to innovation and strategic development across various business segments to navigate industry challenges [2]